194 related articles for article (PubMed ID: 29275295)
61. Poorly differentiated and anaplastic thyroid cancer.
Patel KN; Shaha AR
Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
[TBL] [Abstract][Full Text] [Related]
62. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
[TBL] [Abstract][Full Text] [Related]
63. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
64. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
65. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
66. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
67. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas.
Ensinger C; Prommegger R; Kendler D; Gabriel M; Spizzo G; Mikuz G; Kremser R
Anticancer Res; 2003; 23(3B):2349-53. PubMed ID: 12894514
[TBL] [Abstract][Full Text] [Related]
68. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Krill L; Deng W; Eskander R; Mutch D; Zweizig S; Hoang B; Ioffe O; Randall L; Lankes H; Miller DS; Birrer M
Gynecol Oncol; 2020 Feb; 156(2):423-429. PubMed ID: 31843273
[TBL] [Abstract][Full Text] [Related]
69. The Targetable Epigenetic Tumor Protein EZH2 is Enriched in Intraocular Medulloepithelioma.
Avedschmidt SE; Stagner AM; Eagle RC; Harocopos GJ; Dou Y; Rao RC
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6242-6246. PubMed ID: 27842164
[TBL] [Abstract][Full Text] [Related]
70. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
71. Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.
Antognelli C; Moretti S; Frosini R; Puxeddu E; Sidoni A; Talesa VN
Cells; 2019 Jun; 8(6):. PubMed ID: 31174324
[TBL] [Abstract][Full Text] [Related]
72. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
73. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
74. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
75. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
76. EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas.
Liu B; Pang B; Wang Q; Yang S; Gao T; Ding Q; Liu H; Yang Y; Fan H; Zhang R; Xin T; Xu G; Pang Q
Hum Pathol; 2017 Aug; 66():101-107. PubMed ID: 28666925
[TBL] [Abstract][Full Text] [Related]
77. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
78. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
79. Time trend in tumour size and characteristics of anaplastic thyroid carcinoma.
Han JM; Bae Kim W; Kim TY; Ryu JS; Gong G; Hong SJ; Kim JH; Oh YL; Jang HW; Kim SW; Chung JH; Shong YK
Clin Endocrinol (Oxf); 2012 Sep; 77(3):459-64. PubMed ID: 22458627
[TBL] [Abstract][Full Text] [Related]
80. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
